In a report released today, Francois Brisebois from Oppenheimer maintained a Hold rating on Ovid Therapeutics (OVID – Research Report).
Dwayne Johnson has recently revealed that the inspiration behind releasing his upcoming movie Red One in IMAX was none other ...
Wrestled turned Hollywood star Dwayne 'The Rock' Johnson is facing flak from cinephiles after claiming that it was the ...
The Rock's filmography has been tough sledding in recent years and his latest Christmas-themed project seems to be more of ...
The Rock can always put a wildly positive spin on any of his movies, but his latest promotional clip takes the cake: he’s ...
Oppenheimer analyst Rick Schafer raised the firm’s price target on Nvidia (NVDA) to $175 from $150 and keeps an Outperform rating on the ...
Greece’s Thessaloniki Film Festival ends this evening with a screening of The End, the latest feature project from the ...
Oppenheimer's Limited-Edition Steelbook releases November 19 and comes with 4K and standard Blu-ray discs as well as a ...
Covering the data sector for Oppenheimer, analyst Param Singh is flashing ‘Buy’ signals on two specific data storage stocks.